Literature DB >> 26719539

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Shari Pilon-Thomas1, Krithika N Kodumudi1, Asmaa E El-Kenawi2, Shonagh Russell3, Amy M Weber1, Kimberly Luddy3, Mehdi Damaghi3, Jonathan W Wojtkowiak3, James J Mulé1, Arig Ibrahim-Hashim3, Robert J Gillies4.   

Abstract

Cancer immunotherapies, such as immune checkpoint blockade or adoptive T-cell transfer, can lead to durable responses in the clinic, but response rates remain low due to undefined suppression mechanisms. Solid tumors are characterized by a highly acidic microenvironment that might blunt the effectiveness of antitumor immunity. In this study, we directly investigated the effects of tumor acidity on the efficacy of immunotherapy. An acidic pH environment blocked T-cell activation and limited glycolysis in vitro. IFNγ release blocked by acidic pH did not occur at the level of steady-state mRNA, implying that the effect of acidity was posttranslational. Acidification did not affect cytoplasmic pH, suggesting that signals transduced by external acidity were likely mediated by specific acid-sensing receptors, four of which are expressed by T cells. Notably, neutralizing tumor acidity with bicarbonate monotherapy impaired the growth of some cancer types in mice where it was associated with increased T-cell infiltration. Furthermore, combining bicarbonate therapy with anti-CTLA-4, anti-PD1, or adoptive T-cell transfer improved antitumor responses in multiple models, including cures in some subjects. Overall, our findings show how raising intratumoral pH through oral buffers therapy can improve responses to immunotherapy, with the potential for immediate clinical translation. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719539      PMCID: PMC4829106          DOI: 10.1158/0008-5472.CAN-15-1743

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Blood leukocytes and macrophages of various phenotypes have distinct abilities to form podosomes and to migrate in 3D environments.

Authors:  Céline Cougoule; Emeline Van Goethem; Véronique Le Cabec; Fanny Lafouresse; Loïc Dupré; Vikram Mehraj; Jean-Louis Mège; Claire Lastrucci; Isabelle Maridonneau-Parini
Journal:  Eur J Cell Biol       Date:  2012-09-19       Impact factor: 4.492

Review 2.  Indoleamine 2,3-dioxygenase: from catalyst to signaling function.

Authors:  Francesca Fallarino; Ursula Grohmann; Paolo Puccetti
Journal:  Eur J Immunol       Date:  2012-08       Impact factor: 5.532

3.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

Review 4.  Myeloid-derived suppressor cells in human cancer.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

Review 5.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

6.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry.

Authors:  Junjeong Choi; Woo-Hee Jung; Ja Seung Koo
Journal:  Pathobiology       Date:  2012-07-24       Impact factor: 4.342

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.

Authors:  Zhigang Li; Lixue Dong; Eric Dean; Li V Yang
Journal:  Int J Mol Sci       Date:  2013-10-11       Impact factor: 5.923

View more
  187 in total

Review 1.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Phenotypic transition of tumor cells between epithelial- and mesenchymal-like state during adaptation to acidosis.

Authors:  Yongjun Zhang; Lili Xu; Ping Wang; Huanzhang Jian; Xianghua Shi; Min Jia; Lijun Mo; Zhiming Hu; Hongwei Li; Jinlong Li
Journal:  Cell Cycle       Date:  2019-06-29       Impact factor: 4.534

Review 3.  Acidosis and cancer: from mechanism to neutralization.

Authors:  Arig Ibrahim-Hashim; Veronica Estrella
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

4.  Phenotypic changes of acid-adapted cancer cells push them toward aggressiveness in their evolution in the tumor microenvironment.

Authors:  Mehdi Damaghi; Robert Gillies
Journal:  Cell Cycle       Date:  2016-09-16       Impact factor: 4.534

5.  Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

Authors:  Tina Cascone; Jodi A McKenzie; Rina M Mbofung; Simone Punt; Zhe Wang; Chunyu Xu; Leila J Williams; Zhiqiang Wang; Christopher A Bristow; Alessandro Carugo; Michael D Peoples; Lerong Li; Tatiana Karpinets; Lu Huang; Shruti Malu; Caitlin Creasy; Sara E Leahey; Jiong Chen; Yuan Chen; Helen Pelicano; Chantale Bernatchez; Y N Vashisht Gopal; Timothy P Heffernan; Jianhua Hu; Jing Wang; Rodabe N Amaria; Levi A Garraway; Peng Huang; Peiying Yang; Ignacio I Wistuba; Scott E Woodman; Jason Roszik; R Eric Davis; Michael A Davies; John V Heymach; Patrick Hwu; Weiyi Peng
Journal:  Cell Metab       Date:  2018-04-05       Impact factor: 27.287

6.  Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice.

Authors:  Hiraku Kameda; Masaaki Yamamoto; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

Review 7.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

8.  mTOR Senses Intracellular pH through Lysosome Dispersion from RHEB.

Authors:  Zandra E Walton; Rebekah C Brooks; Chi V Dang
Journal:  Bioessays       Date:  2019-06-03       Impact factor: 4.345

Review 9.  Hypoxia and cellular metabolism in tumour pathophysiology.

Authors:  Scott K Parks; Yann Cormerais; Jacques Pouysségur
Journal:  J Physiol       Date:  2017-02-19       Impact factor: 5.182

Review 10.  Targeting acidity in cancer and diabetes.

Authors:  Robert J Gillies; Christian Pilot; Yoshinori Marunaka; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-30       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.